Gainers

• Axe Compute (NASDAQ:AGPU) shares increased by 23.0% to $4.38 during Wednesday's after-market session. The company's market cap stands at $5.4 million. As per the news, the Q4 earnings report came out yesterday.
• Azenta (NASDAQ:AZTA) stock rose 10.48% to $23.4. The company's market cap stands at $973.2 million.
• Virax Biolabs Group (NASDAQ:VRAX) shares increased by 8.24% to $0.21. The company's market cap stands at $1.6 million.
• Connect Biopharma Hldgs (NASDAQ:CNTB) shares increased by 8.08% to $2.94. The company's market cap stands at $146.4 million. As per the press release, Q4 earnings came out yesterday.
• Stereotaxis (AMEX:STXS) stock increased by 7.05% to $1.98. The company's market cap stands at $178.9 million.
• Bicara Therapeutics (NASDAQ:BCAX) shares rose 6.82% to $21.9. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q4 earnings came out 2 days ago.

Losers

• Alto Neuroscience (NYSE:ANRO) stock decreased by 10.3% to $21.0 during Wednesday's after-market session. The company's market cap stands at $718.1 million.
• CDT Equity (NASDAQ:CDT) stock declined by 10.1% to $4.58. The company's market cap stands at $24.0 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) stock decreased by 9.88% to $1.46. The market value of their outstanding shares is at $21.2 million.
• Onconetix (NASDAQ:ONCO) stock decreased by 7.45% to $1.74. The company's market cap stands at $1.0 million.
• OSR Holdings (NASDAQ:OSRH) stock declined by 6.59% to $0.55. The company's market cap stands at $15.4 million. As per the news, the Q4 earnings report came out yesterday.
• Pasithea Therapeutics (NASDAQ:KTTA) stock declined by 5.92% to $0.7. The market value of their outstanding shares is at $16.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.